Τόμος 18 (2000) – Τεύχος 1 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 18 (2000) – Issue 1 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βασίλης A. Κόκκας,  Κωνσταντίνος Λ. Παπαδόπουλος, Παύλος Κ. Παπαδόπουλος

Εργαστήριο Φαρμακολογίας και Β΄ Καρδιολογική Κλινική, Ιατρικό Τμήμα, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

B.A. Kokkas, C.L. Papadopoulos, P.C. Papadopoulos

Departments of Pharmacology and 2^nd Cardiol­ogy, Medical Scholl, Aristotle University, Thes­saloniki, Greece

2. Staels B., Koenig W., Habi A.: Activation of human aortic smooth muscle cells is inhibited by PPARa but not by PPARγ activators. Letters to nature. Nature 393: 790-793 (1998)

3. Schoonjans K, Staels B, Auwerx J.: The peroxisome proliferator-activated receptors (PPARs) and their effects on lipid metabolism and adiposity differentiation. Biochim. Biophys. Acta 1302: 93-109 (1996)

4. Βraissant O., Foufelle F., Scotto C., Dauca M., Wahli W.: Differential expression of peroxisome proliferator-acti­vated receptors: tissue distribution of PPAR α, β and γ in the adult rat. Endocrinology 137: 354-366 (1996)

5. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al.: tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327 (1997)

6. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., Clark J.B.: Distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptor α , β and γ and the retinoid X receptor α , β and γ in rat nervous system. J. Neurochem. 70: 1366-1375 (1998)

7. Granneman J., Skoff R., Yang X.: Member of perox­isome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J. Neurochem. 51: 563-573 (1998)

8. Chinetti G., Griglio S., Antonucet M., Derrive P., Majd Z., Fruchart J., Chapman J., Najib J., Staels B.: Activation of proliferator-activated receptors alpha and gamma in­duces apoptosis of human monocyte-derived macro­phages. J. Biol. Chem. 273: 25573-25580 (1998)

9. Fruchart J., Duriez P., Staels B.: Peroxisome prolifera­tor-activated receptor-alpha activators regulate genes govern­ing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipid. 10: 245-257 (1999)

10. Fajas L., Fruchart J.-C., Auwerx J.: Transcriptional control of adipogenesis. Curr. Opin. Cell Biol. 10: 165-173 (1998)

11. Mueller E., Sarraf P., Tontionoz P., Evans R.M., Martin K.J., Zhang M., et al.: Terminal differentiation of human breast cancer through PPARγ. Mol. Cell 1: 465-470 (1998)

12. Spiegelman B.: PPAR-gamma adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514 (1998)

13. Murray R.: Cancer, oncogenes and growth factors. In: (Murray R., Granner D., Mayes P., Rodwell V., eds) Harper’s Biochemistry. Pp. 650-663, Prentice-hall Intern. Inc., London, 1990

14. Κόκκας Β.: Θέματα Μοριακής Φαρμακολογίας. Univer­sity Studio Press. Θεσσαλονίκη, 1999

15. Staels B., Koenig W., Habib A., Merval R., Lebret M., Pineda Torra I., et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ acti­vators. Nature 393: 790-793 (1998)

16. Ricote M., Li A.C., Willsson T.M., Kelly C.J., Glass C.K.: The peroxisome proliferator-activated receptor-γ is a nega­tive regulator of macrophage activation. Nature 391: 79-82 (1998)

17. Jiang C., Ting A., Seed B.: PPARγ-agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86 (1996)

18. Fajas L., Fruchart J., Auwerx J.: Transcriptional control of adipogenesis. Curr. Opin. Biol. 10: 165-173 (1998)

19. Aoyama T., Peters J., Iritani N., Nakajima T., Furihata K., Hassimoto T.: Altered constitutive expression of fatty acid metabolising enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J. Biol. Chem. 273: 5678-5684 (1997)

20. Mascaro C., Acosta E., Ortiz J., Marrero P., Hegardt F., Haro D.: Control of human muscle-type carnitine palmitoyl­transferase I gene transcription by peroxisome proliferator-activated receptor. J. Biol. Chem. 273: 8560-8563 (1998)

21. Brandt J., Djouadi F., Kelly D.: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 273: 23786-23792 (1998)

22. Inoue I., Satoru N., Shem M., Takahashi K., Nakajima S.: The peroxisome proliferator-activated receptor α (PPARα) regulates the plasma thiobarbituric acid reactive substance (TBARS) level. Biochem. Biophys. Res. Com­mun. 237: 606-610 (1997)

23. Randle P., Garland P., Hales C., Newsholme E.: The glucose fatty acid cycle, its role in insulin sensitivity and the metabolic pertubances of diabetes mellitus. Lancet 1: 785-794 (1963)

24. Boden G., Jadali F.: Effects of lipids on basal carbohy­drate metabolism in normal men. Diabetes 40: 666-692 (1991)

25. Komers R., Vrana A.: Thiazolidinediones – tools for the research of metabolic syndrome X. Physiol. Res. 47: 215-225 (1998)

26. Reaven G.: Role of insulin resistance in human dis­ease (syndrome X): an expanded definition. Ann. Rev. Med. 44: 121-131 (1993)

27. Despress J.: Abdominal obesity as important compo­nent of insulin-resistance syndrome. Nutrition 9: 452-459 (1993)

28. Poynter M., Daynes D.: PPARα activation modulates cellular redox status, repress NFκB signalling and reduces inflammatory cytokines production in aging. J. Biol. Chem. 273: 32833-32841 (1998)

29. Wilson M., Walhi W.: Peroxisome proliferator -acti­vated receptor agonists. Cur. Opin. Chem. Biol. 1: 235-241 (1997)

30. Kim J., Wright H., Wright M., Spiegelman B.: ADD1/SREBP1 activates PPARγ through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA 95: 4333-4337 (1998)

31. Fan C., Pan J., Usuda N., Yeldandi A. , Rao M., Reddy J.: Steatohepatitis, spontaneous peroxisome prolif­eration and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J. Biol. Chem. 273: 15639-15645 (1998)

32. Nagy L., Tontoroz P., Alvarez J., Chen H., Evans R.: Oxidized LDL regulates macrophages gene expression through ligand activation of PPARγ. Cell 93: 229-240 (1998)

33. Schonfeld G.: The effect of fibrates on lipoprotein and hemostatic coronary risk factors . Atherosclerosis 111: 161-174 (1994)

34. Chapman MJ., Guerin M., Bruckert E.: Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J. 19 (Suppl A): A24-A30 (1998)

35. Witzum J.: Drugs used in the treatment of hyperlipo­proteinemias. In: (Hardman J., Limbird L. eds) Goodman and Gilman’s. The pharmacological Basis of Therapeutics. Pp. 875-897, McGraw-Hill, New York, 1996

36. Lefebre A., Peinado-Onsubre J., Leittersdorf I., Brigge M., Paterniti J.: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but comple­mentary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17: 1756-1764 (1997)

37. Packer L., Rimbach G., Virgili F.: Antioxidant activity and biologic properties of a procyanidin rich extract from pine (pinus maritima) bark, pycnogenol. Free Rad. Biol. Med. 27: 704-724 (1999)